Medical articles today

/* 728x15, */

Chronicle Of American School Of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS R Liberte R Stent

/* 468x60, */

Boston Scientific Partnership (NYSE: BSX) welcomed the publication of an article in the current edition of the Log of American College of Cardiology (JACC) reviewing data on more than 19,000 patients from the Swedish national registry who were evaluated for restenosis, or the re-narrowing of arteries after percutaneous coronary intervention (PCI). The article reported that patients who received a TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent had numerically lower incidences of repeat procedures to treat restenosis at two senility as compared to patients treated with 'olimus-based drug-eluting stents (DES), including Cordis' Cypher(R) Stent and Medtronic's Endeavor(R) Stent. In the patients with diabetes, the TAXUS Liberte Stent demonstrated a statistically significant lower restenosis standard compared to the Endeavour Stent, which had extra than two times the risk of repeat procedures.
The Swedish Coronary Angiography and Angioplasty Registry holds data on all patients undergoing PCI in Sweden. The purpose of this independent discover was to evaluate restenosis rates of drug-eluting stents in patients with and without diabetes in a real-world setting. The JACC article reported that both the TAXUS Liberte Stent and Boston Scientific's first-generation DES -- the TAXUS(R) Express(R) Stent -- were the only stents in the study showing no increased risk of restenosis for patients with diabetes as compared to those without diabetes. Both the Cypher Stent and Endeavor Stent showed significant increased risk of restenosis in patients with diabetes. In addition, the scan showed that the TAXUS Liberte Stent had an approximately 23 percent lower restenosis rate at two elderliness compared to the prior-generation TAXUS Express Stent. The authors concluded that "There seem to be relevant differences between at odds brands of DES."(1)
"The results of this study are noteworthy for TAXUS Liberte, which compared favourably in rates of repeat procedures to both 'olimus stents," said Donald S. Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "The findings presented in the article are consistent with our own clinical trial observations, including recently published ARRIVE and ATLAS data, and may give forth the different mechanism of enterprise for paclitaxel compared to the 'olimus agents used in the other drug-eluting stents. The newer and thinner-strut TAXUS Liberte Stent performed better than the TAXUS Clear-cut Stent in reducing restenosis."
The Swedish registry peruse included four DES brands: TAXUS Liberte, TAXUS Express, Cypher and Endeavor. In total, the registry included 35,478 DES implants during 22,962 procedures in 19,004 patients, with 1,807 restenoses reported over a penny-pinching 29-month follow-up period. For the comprehensive study population, the repeat revascularization scale per stent was 3.5 percent after one year and 4.9 percent after two years. Overall, the adjusted risk of restenosis was 1.23 times higher in patients with diabetes than in patients without diabetes. In patients with diabetes, restenosis was higher in the non-TAXUS Stents. The sirolimus-eluting Cypher Stent and the zotorolimus-eluting Endeavor Stent had higher restenosis rates in patients with diabetes compared with those in patients without diabetes (1.25 times and 1.77 times, respectively).
"The Swedish recite shows there are eloquent distinctions among available DES, as well as differences between first- and second-generation products," said Twist Kucheman, Senior Vice Head of the state and Collection President, Cardiovascular for Boston Scientific. "Our two-drug strategy has allowed us to maintain our global DES direction position by offering the next-generation TAXUS Liberte Stent as hardy as the PROMUS(R) Everolimus-Eluting Coronary Stent. We glimpse forward to introducing our third-generation Element(TM) Stent on both narcotic platforms successive this year in CE Speck countries."
TAXUS Stents annex been evaluated by the industry's most spread out randomized, controlled clinical trial program, with follow-up to five years in some cases. These check results have been supplemented by material on besides than 35,000 patients enrolled in post-approval registries. To date, sorrounding 11 million Boston Scientific stents admit been implanted globally, forming them the world's most often used stents.
The TAXUS Liberte Paclitaxel-Eluting Coronary Stent Manner received U.S. Eatable and Drug Governance approval in October 2008, and received European CE Mark approval for utilize in patients with diabetes in December 2007. In the United States, the TAXUS Stents are not specifically indicated for convenience in patients with diabetes.
The PROMUS Stent is a private-labeled XIENCE V(R) Everolimus-Eluting Coronary Stent Method manufactured by Abbott and distributed by Boston Scientific. XIENCE V is a trademark of the Abbott Laboratories group of companies. Cypher is a trademark of Cordis Corporation. Endeavor is a trademark of Medtronic Vascular, Inc.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a wide range of interventional medical specialties.
(1) (J Am Coll Cardiol 2009;53:1660-7)
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Convert Act of 1934. Forward-looking statements may be identified by paragraph approximative "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and complementary words. These forward-looking statements are based on our beliefs, assumptions and estimates using hookup available to us at the time and are not intended to be guarantees of likely events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. Provided our underlying assumptions turn absent to be incorrect, or whether sure risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could influence our power to apparatus our business strategy and may reason actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may antecedent such differences include, among other things: approaching economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, coming up livelihood decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and distinct of them are beyond our control. For a extremely list and discription of these and other crucial risks and uncertainties that may affect our final operations, see Part I, Thing 1A - Risk Factors in our most advanced Annual Announcement on Form 10-K filed with the Securities and Transform Commission, which we may modernize in Part II, Object 1A - Risk Factors in Quarterly Reports on Form 10-Q we own filed or testament file thereafter. We disclaim any goal or obligation to publicly update or revise any forward-looking statements to copy any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may prevail the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Source: Boston Scientific Corporation
/* 468x60, */

Keywords:

stent, liberte stent, coronary stent, stent chronicle, cypher stent, stent boston, stent endeavor, stent reducing, stent manner, stent xience
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy